Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.
Real patient experiences show that a newer lymphoma treatment improves quality of life compared to older chemotherapy, helping people make informed choices.
This Phase 3 RCT reports patient-reported quality of life outcomes from the FLAIR trial comparing ibrutinib-rituximab versus standard FCR chemoimmunotherapy in previously untreated CLL. The QoL data adds a critical patient-centered dimension to first-line CLL treatment decision-making.
What the study was
- Study design
- Randomized controlled trial (Phase 3)
- Population
- Previously untreated CLL patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- British Journal of Haematology
Why it surfaced
Phase 3 RCT QoL data directly informing CLL first-line treatment choice between ibrutinib-rituximab and FCR.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.